Severe Hyponatremia and Immune Nephritis Following an Initial Infusion of Nivolumab

Targeted Oncology

Volumn 11, Issue 4, 2016, Pages 553-556

  Vandiver, Jeremy W ^a,b   Singer, Zachary ^b   Harshberger, Cara ^a  

^a UNIVERSITY OF WYOMING SCHOOL OF PHARMACY   (United States)

^b Swedish Family Medicine Residency   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NIVOLUMAB; MONOCLONAL ANTIBODY;

ABNORMAL RESPIRATORY SOUND; ADULT; ARTICLE; CANCER STAGING; CASE REPORT; CLINICAL FEATURE; DISEASE SEVERITY; DRUG EFFECT; DRUG SAFETY; DYSPNEA; FEMALE; HEART PALPITATION; HUMAN; HYPONATREMIA; IMMUNE COMPLEX NEPHRITIS; METASTATIC MELANOMA; MIDDLE AGED; PHYSICAL EXAMINATION; PRIORITY JOURNAL; TACHYCARDIA; CHEMICALLY INDUCED; NEPHRITIS;

ANTIBODIES, MONOCLONAL; FEMALE; HUMANS; HYPONATREMIA; MIDDLE AGED; NEPHRITIS;

EID: 84960076189     PISSN: 17762596     EISSN: 1776260X     Source Type: Journal    
DOI: 10.1007/s11523-016-0426-9     Document Type: Article

References (9)

1. Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711–23.
2. Robert C, Long GV, Brady B, Dutriaux C, Maio M, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372:320–30.
3. Postow MA, Chesney J, Pavlick AC, Robert C, Grossman K, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med. 2015;372(21):2006–17.
4. Weber JS, D’Angelo SP, Minor D, Hodi FS, Gutzmer R, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2015;16:375–84.
5. Opdivo [package insert]. Princeton, NJ: Bristol-Meyers Squibb; 2016.
6. Nivolumab Clinical Trials. U.S. National Library of Medicine. 2013. https://clinicaltrials.gov/ct2/results?term=nivolumab&Search=Search. Accessed 21 Sept 2015.
7. Luke JJ, Ott PA. PD-1 pathway inhibitors: the next generation of immunotherapy for advanced melanoma. Oncotarget. 2015;6(6):3479–92.
8. Barbee MS, Ogunniyi A, Horvat TZ, Dang T. Current status and future directions of the immune checkpoint inhibitors ipilmumab, pembrolizumab, and nivolumab in oncology. Ann Pharmacother. 2015;49(8):907–37.
9. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239–45.